Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Evidence Based Care of Alopecia Areata
Description
The presentation discusses the evidence-based treatment of Alopecia Areata (AA), emphasizing the evolution of treatment and the development of new evidence-based guidelines. The speaker, who has extensive experience with AA treatments and clinical trials, highlights the importance of understanding disease severity and individual patient impact. Shared decision-making is crucial, as treatment goals differ among patients. Current FDA-approved therapies for severe AA include JAK inhibitors like baricitinib, which show varying degrees of effectiveness, often requiring extended treatment periods for optimal results. The discussion covers the prevalence of the condition, epidemiology, and emphasizes managing patient expectations about treatment timelines. It also critiques older medications, promoting newer therapies and a patient-centered holistic approach. The speaker notes that while significant therapeutic development has occurred, limitations exist for moderate to mild disease types, necessitating ongoing innovation. A focus on individual patient experiences and perceptions of disease impact is essential in formulating treatment plans, and engaging patients in their care process improves outcomes. Emerging treatments and ongoing clinical trials indicate a promising future for AA therapies.
View moreConclusions
- Current treatment guidelines for alopecia areata (AA) are being developed, and comparative cost data is lacking.
- The management of AA is evolving with new drug innovations and a better understanding of the disease.
- Shared decision-making is critical in treatment planning for AA, as individual patient perspectives greatly influence care.
- Older treatments for AA are often ineffective and should be replaced by more effective therapies.
- Intralesional steroids remain a cornerstone for treating patchy AA, while topical steroids have limited efficacy.
- JAK inhibitors such as baricitinib and ritlecitinib have shown significant promise in treating severe AA.
- Short-term use of systemic steroids may be beneficial but should be avoided long-term due to potential adverse effects.
- Patient responses to treatment can vary widely, and some individuals may take longer to see benefits from medications.
- The severity of AA is subjective, and treatment decisions should be centered on the patient's needs and concerns.
- Lipid monitoring may be more critical when using baricitinib compared to ritlecitinib, as the latter has a different safety profile.
- King B et al. DOI: 10.1056/NEJMoa2110343